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abstractBACKGROUND AND OBJECTIVES: Atopic dermatitis (AD) primarily affects infants and young children.
Although topical corticosteroids (TCSs) are often prescribed, noncorticosteroid treatments are
needed because compliance with TCSs is poor due to concerns about their side effects. In this
longest and largest intervention study ever conducted in infants with mild-to-moderate AD,
pimecrolimus 1% cream (PIM) was compared with TCSs.
METHODS: A total of 2418 infants were enrolled in this 5-year open-label study. Infants were
randomized to PIM (n = 1205; with short-term TCSs for disease flares) or TCSs (n = 1213). The
primary objective was to compare safety; the secondary objective was to document PIM’s
long-term efficacy. Treatment success was defined as an Investigator’s Global Assessment
score of 0 (clear) or 1 (almost clear).
RESULTS: Both PIM and TCSs had a rapid onset of action with .50% of patients achieving
treatment success by week 3. After 5 years,.85% and 95% of patients in each group achieved
overall and facial treatment success, respectively. The PIM group required substantially fewer
steroid days than the TCS group (7 vs 178). The profile and frequency of adverse events was
similar in the 2 groups; in both groups, there was no evidence for impairment of humoral or
cellular immunity.
CONCLUSIONS: Long-term management of mild-to-moderate AD in infants with PIM or TCSs was
safe without any effect on the immune system. PIM was steroid-sparing. The data suggest PIM
had similar efficacy to TCS and support the use of PIM as a first-line treatment of mild-to-
moderate AD in infants and children.
WHAT’S KNOWN ON THIS SUBJECT: Topical
corticosteroids are often used to treat atopic
dermatitis (AD) in infants, although compliance
is poor due to concerns over side effects.
Pimecrolimus was shown to be a safe and
effective noncorticosteroid treatment of AD in
infants in short-term studies.
WHAT THIS STUDY ADDS: The Petite Study shows
that long-term management of mild-to-moderate
AD in infants with pimecrolimus or topical
corticosteroids was safe without any effect on
the developing immune system. Pimecrolimus
had similar efficacy to topical corticosteroids
and a marked steroid-sparing effect.
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Atopic dermatitis (AD) is a chronic
inflammatory, relapsing, and pruritic
skin disease that affects up to 25% of
infants and has a substantial impact
on the quality of life of both patients
and their families.1–3 AD, together
with food allergy, is thought to be the
first step of the “atopic march,” in
which allergen exposure of the skin
can lead to the subsequent
development of asthma and allergic
rhinoconjunctivitis.4 Patients with AD
often need frequent interventions for
disease flares and sometimes long-
term continuous therapy to suppress
the inflammation of the skin. Topical
corticosteroids (TCSs) are commonly
used as first-line treatment of AD,5
although their long-term safety and
efficacy have not been investigated in
infants. More than 80% of patients or
caregivers have concerns about
prescribed TCSs, and approximately
one-third of AD patients are
noncompliant with TCSs because of
factors such as their potential side
effects,6 which highlights the need for
alternative noncorticosteroid
treatments.
Pimecrolimus cream 1% (PIM) is
a topical calcineurin inhibitor that
selectively suppresses activation of
T cells and mast cells.7,8 PIM is often
recommended by prescribers as first-
line AD therapy for sensitive skin
areas because it causes neither
epidermal barrier function
impairment nor skin atrophy.5,9,10 Up
to 2 years of PIM is effective and well
tolerated in infants and children with
mild-to-moderate AD.11–16 The Petite
Study sought to compare the safety
and efficacy of PIM and TCSs for the
management of mild-to-moderate
infantile AD during 5 years of
evaluation. The safety analysis
included several assessments of
immune function, given concerns that
PIM-mediated immunomodulation
could affect the developing immune
system. The study used a unique real-
world design in which TCSs were
used according to their label and in
which the caregivers of infants
randomized to treatment with PIM
had ready access to short-term TCSs
as rescue medication if AD flares
could not be controlled with PIM.
METHODS
Patient Population
Patients were enrolled into the study
between April 2004 and October
2005. Eligible infants were aged $3
to ,12 months, and AD was
diagnosed according to the criteria of
Seymour et al17 (because these
criteria were developed for patients
aged #2 years) with disease affecting
$5% of the total body surface area
(TBSA). Patients had an Investigator’s
Global Assessment (IGA) score of 2 or
3 (scale range: 0–5; Supplemental
Table 3), indicating mild-to-moderate
disease.
Patients were excluded if they used
systemic corticosteroids,
immunosuppressants, cytostatic
drugs, or phototherapy within
4 weeks of the first application of
study medication, topical tacrolimus
ointment or PIM within 2 weeks, and
topical therapy for AD such as TCSs
within 3 days. Also excluded were
immunocompromised patients and
those with a history of malignant
disease, active acute viral skin
infection, or clinically infected AD.
Study Design
The primary objective of this 5-year,
multicenter, open-label, randomized,
parallel group study (www.
clinicaltrials.gov identifier
NCT00120523) was to compare the
safety of PIM and TCSs over the first 5
to 6 years of life by assessing adverse
events (AEs), and the effects of
treatments on the developing
immune system and growth rate. The
secondary objective was to examine
the long-term efficacy of PIM.
Patients were randomized in a 1:1
ratio to either PIM 1% cream or TCS
(low potency, eg, hydrocortisone 1%;
or medium potency, eg,
hydrocortisone butyrate 0.1%;
cream/ointment used according to
the country’s label with potency
selected by the investigator), and
randomization was stratified by
center and age group (3–6 and
.6–,12 months) using a validated
Interactive Voice Response System.
Details of the treatment plan are
shown in Supplemental Table 4.
Study medication was started
immediately after randomization and
continued until complete AD
clearance or for as long as allowed by
the label of the specific TCS.
Medication was reinitiated at the
occurrence of first signs and
symptoms of AD flares. Investigators
explained to caregivers of patients in
both groups what constituted disease
worsening and, to those in the PIM
group, when to stop PIM and start
using a TCS, that is, as a rescue
medication for an exacerbation not
controlled by PIM.
The study was conducted in
accordance with Good Clinical
Practice and the Declaration of
Helsinki. The study protocol was
approved by the Independent Ethics
Committee or Institutional Review
Board for each center. Caregivers
provided written informed consent
for infants’ participation in the study.
Efficacy and Safety Assessments
Efficacy was evaluated by
investigators during clinic visits using
the IGA (range 0–5) for the whole
body with a score of 0 (clear) or 1
(almost clear) indicating treatment
success, and the TBSA affected by
inflammation. Special consideration
was given to facial AD. These
straightforward and non–time-
consuming efficacy assessments were
considered suitable for this large-
scale clinical study.
All AEs were coded by system organ
class and preferred term according to
the Medical Dictionary for Regulatory
Activities (version 13.1). (AEs of
primary clinical interest as defined by
the US Food and Drug Administration
are identified in Fig 3 later in the
article.) Growth rate was assessed by
measuring height and weight at each
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visit. AEs recorded for the PIM group
may have occurred either during
treatment with PIM or with TCS for
a flare.
Immunology assessments included
antibody titers to common vaccine
antigens, evaluations of humoral and
cellular immune responses, and T-cell
function tests (see Supplemental
Information).
Statistical Analysis
The safety and intent-to-treat
populations included all randomized
patients who received at least 1
application of study medication.
Assuming a 40% dropout rate,
a sample size of 2350 infants was
considered to provide $80% or
$90% power to determine whether
the AE incidence rates under varying
scenarios were equivalent in the
treatment groups. This calculation
assumed that the expected true
difference was zero and used the
upper bound of the 97.5% confidence
interval as the upper equivalence
limit. The immunology test
population comprised all patients
who had at least 1 immune system
function assessment and was to
include ∼350 patients per treatment
group. All significance testing was
2-sided at the 5% significance level.
The primary safety analyses were
performed on AEs of primary clinical
interest and those with a crude
incidence of $5% in either treatment
group. These included Kaplan-Meier
analysis of time to first occurrence of
the AE. AE profiles for the treatment
groups were compared using the log-
rank test. Additionally, AE counts in
specific time intervals were analyzed
using a Generalized Estimating
Equations Poisson regression model
with baseline age and IGA, time, and
treatment as explanatory variables.
The crude incidence rate and relative
risk based on the incidence density
rate were also calculated for the AEs
of primary clinical interest. The
incidence density rate per 1000
person-months was calculated as
1000 3 total number of events / total
monitoring time in months (ie, sum of
study durations in months across all
patients in a treatment group).
The presence or absence of antibody
titers against vaccines was analyzed
using a logistic regression model with
time of vaccination, age group, and
treatment as explanatory variables.
Treatment group differences in
percentage change from baseline to
each postbaseline time point in T
and B lymphocytes, and
immunoglobulins (Ig) were evaluated
together with 95% confidence
intervals calculated under the
assumption of equal variances using
pooled variance. Candida skin and
T-cell function tests were reported
with descriptive statistics.
Analysis of growth rate was done by
calculating the percentile and z score
for height and weight for each patient
at time points defined in the protocol
using standard growth curves for the
US population.18 The mean and
change from baseline for observed
height and weight as well as
percentiles were summarized by
treatment group at each time point.
A mixed model analysis of the growth
curve data were also performed to
examine developmental trajectories
with height and weight z scores as the
response variable and time and
treatment as explanatory variables.




Overall, 2439 infants were
randomized into the study, 2418 of
whom received at least 1 dose of
study drug (PIM, 1205; TCS, 1213)
and were included in the efficacy and
safety evaluations. A similar
proportion of patients in each group
completed the treatment period: PIM,
69.4%; TCS, 72.1% (Fig 1). The
baseline demographic and clinical
characteristics of the treatment
FIGURE 1
Patient disposition.
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groups were similar (Table 1). On
inclusion, the majority of patients
were 6 to 12 months old. Although
the study was designed to enroll
infants aged $3 to ,12 months, 15
patients older than 12 months (14
patients ,12.5 months old; 1 patient
12.8 months) were entered and
included in the analyses. The 383
PIM- and 391 TCS-treated patients
in the immunology test population
had similar baseline characteristics
to the overall population (data not
shown).
Efficacy
Both PIM and TCSs had a rapid onset
of action (Fig 2). More than 50% of
infants in both groups achieved
overall (PIM, 52.6%; TCS, 50.5%) or
facial IGA (PIM, 61.0%; TCS, 61.8%)
treatment success (ie, IGA #1) by
week 3. The median TBSA affected by
AD decreased from 16% at baseline
to ,5% by week 3 (PIM, 3.8%; TCS,
4.0%; Fig 2). At the end of the 5-year
study, .85% (PIM, 88.7%; TCS,
92.3%) and 95% (PIM, 96.6%; TCS,
97.2%) of patients achieved overall
and facial IGA treatment success,
respectively (Fig 2A and 2B).
Similarly, the median TBSA affected
by AD decreased to 0% after 1.5 years
of “as-needed” treatment and was
maintained at this level for the rest of
the study (Fig 2C).
TCS and Pimecrolimus Exposure
PIM was associated with a steroid-
sparing effect. Thirty-six percent of
patients in the PIM group did not use
any TCSs. Overall, the patients in the
PIM group used TCSs for a median of
only 7 days (Q1: 0, Q3: 49 days)
compared with 178 days (Q1: 77, Q3:
396 days) in the TCS group over the
5-year study period (Supplemental
Fig 5). Patients in the PIM group used
PIM for a median of 224.5 days (Q1:
90, Q3: 452 days).
Safety
The frequency of the most common
AEs was similar in both treatment
groups (Supplemental Table 5). There
were few discontinuations due to AEs
(PIM, 0.6% [most common:
application site reactions, 3 patients];
TCSs, 1.0% [most common:
telangiectasia, 2 patients]). There was
no difference in growth rate between
the groups or in the Kaplan-Meier
adjusted incidence of frequent AEs
($5%) or AEs of primary clinical
interest, such as bacterial or viral
infections. Analysis of event counts
for frequent AEs using the repeated
Poisson regression model showed
that patients in the PIM group
experienced more AEs of bronchitis
(P = .02), infected eczema (P , .001),
impetigo (P = .045), and
nasopharyngitis (P = .04). During the
first 6 weeks and the entire study, the
crude incidence and incidence
density rate for the AEs of primary
clinical interest were similar (Fig 3).
There were no differences in the
Kaplan-Meier analysis of the time to
first occurrence of these AEs.
Two deaths were reported in the TCS
group, but considered unrelated to
study medication (drowning, acute
lymphocytic leukemia). The overall
incidence of SAEs (PIM, 20.5%; TCS,
17.3%) and serious infections and
infestations (13.0% vs 12.4%) were
similar in the 2 groups. Two
malignancies occurred in the TCS
group (acute lymphocytic leukemia,
ependymoma), and 1 benign tumor
was reported in the PIM group
(pilomatrixoma).
Immune System
Infants treated with PIM or TCSs
developed similar and normal
antibody titers to common vaccine
antigens (Table 2). To evaluate the
magnitude of the antibody response of
infants being treated with study drug
after immunization, the response to
Haemophilus influenza type b vaccine
was assessed by measuring antibody
titers before the third dose of primary
vaccination and 30 days
TABLE 1 Patient Baseline Demographic and Disease Characteristics
PIM 1% (n = 1205) TCS (n = 1213)
Age, mo
Mean (SD) 7.1 (2.7) 7.1 (2.7)
,3, n (%) 4 (0.3) 7 (0.6)
3–6, n (%) 500 (41.5) 485 (40.0)
.6–,12, n (%) 694 (57.6) 713 (58.8)
$12, n (%) 7 (0.6) 8 (0.7)
Gender, n (%)
Male 744 (61.7) 742 (61.2)
Race, n (%)
Caucasian 736 (61.1) 713 (58.8)
Black 66 (5.5) 80 (6.6)
Asian 119 (9.9) 118 (9.7)
Other 284 (23.6) 302 (24.9)
TBSA affected
Mean (SD) 21.1 (16.5) 21.3 (17.2)
,15%, n (%) 568 (47.1) 575 (47.4)
15–,30%, n (%) 378 (31.4) 367 (30.3)
$30%, n (%) 259 (21.5) 271 (22.3)
IGA, n (%)
2, Mild disease 570 (47.3) 558 (46.0)
3, Moderate disease 635 (52.7) 652 (53.8)
4, Severe disease 0 2 (0.2)
5, Very severe disease 0 1 (0.1)
Facial IGA, n (%)
0, Clear 71 (5.9) 74 (6.1)
1, Almost clear 88 (7.3) 84 (6.9)
2, Mild disease 497 (41.2) 501 (41.3)
3, Moderate disease 541 (44.9) 537 (44.3)
4, Severe disease 7 (0.6) 15 (1.2)
5, Very severe disease 1 (0.1) 1 (0.1)
Not stated 0 1 (0.1)
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postimmunization in a subset of
patients. In both groups, all patients
but 1 were seropositive (Table 2).
The increase in Ig levels and the
decrease in peripheral blood T and
B lymphocytes from baseline to week
260 were similar in both groups
(Fig 4, Supplemental Fig 6) and
considered normal compared with
historical controls (for example, see
Supplemental Fig 7). The proportion
of patients with positive Candida skin
tests was similar between treatment
groups (baseline: PIM, 14.0%; TCS,
9.2%; week 260: 15.3% vs 14.3%).
T-cell function was assessed by ex vivo
cytokine production in response to
stimulation with anti-CD3 antibodies
and tetanus antigen. Accordingly, the
production of interleukin (IL)-2, IL-4,
IL-10, and interferon-g was
comparable in the 2 treatment groups,
indicating a similar non–antigen




We investigated the safety and
efficacy of PIM and TCSs in the largest
population of infants with AD and for
the longest time period (ie, the first
5–6 years of life) ever studied. Infants
aged $3 to ,12 months were
selected for inclusion so that the
effects of treatment could be
investigated from early infancy
through early childhood. The efficacy
results suggest that PIM has similar
efficacy to TCSs in a real-world
setting, which is noteworthy because
PIM is not currently widely used as
first-line therapy for AD, given the
perception of lower efficacy than
TCSs.19 Both treatments had a rapid
onset of action (within 3 weeks).
After 5 years of as-needed treatment,
88.7% PIM-treated and 92.3% TCS-
treated infants had only minimal
disease, which could reflect
a progressive increase in treatment
efficacy and/or the natural
progression of AD, which tends to get
milder as children get older. The rapid
and continuous improvement in AD
may decrease the substantial physical
and emotional burden caused by this
distressing skin condition.20 These
findings confirm and extend those
from previous shorter studies in
infants and young children, which
FIGURE 2
Long-term efficacy of PIM compared with TCSs: A, overall; B, facial IGA treatment success (IGA #1); C,
TBSA affected. IGA treatment success is defined as an IGA score of 0 (clear) or 1 (almost clear).
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showed that PIM leads to rapid relief
of pruritus, prevention of progression
to major flares, and increases in the
number of disease-free days.11,12,21,22
Treatment with PIM resulted in
a substantial corticosteroid-sparing
effect, with 36% of children not
requiring any TCSs over the 5-year
study. Patients in the PIM group
used TCSs for a median of only 7
days. The markedly decreased need
for TCSs is important because it
FIGURE 3
Crude incidence and relative risk for AEs of primary clinical interest during (A) 6 weeks and (B) entire treatment period. Incidence density ratio was
calculated as 1000 3 total number of events / total monitoring time in months. CI, confidence interval.
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indicates that AD patients can be
effectively treated with
a noncorticosteroid alternative. Up to
one-third of patients are not compliant
with TCS treatment because of
corticophobia, resulting from factors
such as fear of their potential side
effects.6,23–25 The steroid-sparing
effect of PIM may help to improve
treatment compliance, although this
was not specifically assessed in the
Petite Study.
In this 5-year study, there were no
safety concerns with real-life use of
PIM or TCSs. Overall, the type and
frequency of AEs including infections
were as expected for this patient
population.26,27 There were no cases of
T-cell lymphoma or skin malignancies
with PIM during the study, in
agreement with the findings of several
long-term epidemiologic studies.28,29
There was an overall trend toward
PIM being associated with a lower
risk of rhinorrhea, wheezing, viral
rash and lower respiratory tract
infection over the entire treatment
period (Fig 3). However, the
incidence of some mild infections
(bronchitis, impetigo,
nasopharyngitis, infected eczema)
was significantly higher with PIM
than with TCSs. In contrast,
a randomized double-blind study in
adults reported a higher incidence of
infections with TCSs.30 The
differences in AE incidence between
groups were only 2% to 4%, and the
analyses were not adjusted for the
multiplicity of comparisons.
TABLE 2 Patients With Positive Antibody Titresa
Vaccine PIM 1% (n = 383) TCS (n = 391) OR (95% CI)
n/N (%) n/N (%)
Tetanus 164/180 (91.1) 169/190 (88.9) 0.8 (0.5–1.2)
Hepatitis B 63/182 (34.6) 73/191 (38.2) 1.2 (0.9–1.6)
Measles 180/182 (98.9) 181/188 (96.3) 0.8 (0.5–1.2)
Varicellab 27/31 (87.1) 37/44 (84.1) 2.2 (1.0–4.7)
Hibc 26/27 (96.3) 30/31 (96.8) 0.9 (0.1–14.6)
CI, confidence interval; Hib, Haemophilus influenza type b; n/N, number of patients with positive antibody titers / total
number of patients with antibody titer measurements; OR, odds ratio.
a At week 260 for tetanus, hepatitis B, measles, varicella; 30 d postimmunization and before third dose for HIB.
b Only assessed for patients from the United States (PIM 1%, n = 104; TCS, n = 108).
c Only assessed in subset of patients from the United States and Canada.
FIGURE 4
Ig levels over time: A, IgA; B, IgE; C, IgG; and D, IgM.
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Therefore, the clinical significance of
the observed small differences in the
incidence of 4 specific AEs needs to
be interpreted with caution.
The immunologic investigations in
this study represent the most
comprehensive assessment ever
performed of the impact of real-life
AD treatment on the maturation of
the immune system in a large
international population of infants
with AD during the first 5 to 6 years
of life. Our study did not include
a placebo arm for ethical reasons;
however, the increase in Ig levels and
decrease in circulating T and
B lymphocytes were similar in both
groups and consistent with the
normal maturation of the systemic
immune system in healthy
children.31–36 Previous studies have
shown that IgG and IgA levels
progressively rise during the first
years of life in healthy children. IgE
also rises, but to a lesser extent, and
the levels of IgM plateau before those
of the other Ig categories, in
agreement with our findings.31–34
Also similar to our observations,
other studies have demonstrated that
T and B lymphocyte counts peak in
the first 1 to 2 years of life, followed
by a slow decline to adult levels over
time.35,36 The postvaccination
antibody titers showed that most
patients developed a normal immune
response to childhood vaccinations,
and the response was similar in the 2
treatment groups. The current
immunologic data confirm previous
investigations demonstrating that up
to 2 years of PIM treatment in infants
did not result in an increased rate of
systemic or skin infections and
development of immune responses
after vaccination were
normal.11,12,16,21,37 These results
provide important real-world data
supporting the safety of PIM in
infants and young children with
a developing immune system. The
lack of systemic immunosuppression
is likely due to the minimal systemic
drug exposure in both infants and
children.38,39
CONCLUSIONS
The Petite Study begins to address
recommendations from regulatory
agencies and The Topical
Calcineurin Inhibitor Task Force of
the American College of Allergy,
Asthma and Immunology that more
studies are needed to address
questions about the efficacy and
safety of topical immunosuppressive
medications specifically in pediatric
populations with AD.40 The results
of the Petite Study show for the first
time that as-needed first-line
treatment with PIM or TCSs has no
safety concerns and no impact on
the maturation of the developing
immune system. The data suggest
that PIM had similar efficacy to TCS
and PIM was associated with
a substantial corticosteroid-sparing
effect. The study provides real-world
data for the use of PIM as a first-line
treatment of mild-to-moderate AD in
infants and children.
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